Andrea Talacchi1, Francesco Muggiolu2, Antonella De Carlo2, Antonio Nicolato3, Francesca Locatelli4, Mario Meglio2. 1. Department of Neurological Science and Movement, University of Verona, Verona, Italy. Electronic address: andrea.talacchi@univr.it. 2. Department of Neurological Science and Movement, University of Verona, Verona, Italy. 3. Department of Neurosciences, Section of Neurosurgery, Azienda Ospedeliera Universitaria Integrata, Verona, Italy. 4. Department of Public Health and Community Medicine, Section of Epidemiology and Medical Statistics, University of Verona, Verona, Italy.
Abstract
OBJECTIVE: Owing to their rarity and proteiform pathologic features, the clinical behavior of atypical meningiomas is not yet well characterized. Though the extent of resection is believed to be a key determinant of prognosis, limited data exist regarding optimal management of patients with recurrent disease. METHODS: In this 20-year retrospective case series, we reviewed the medical records of 46 patients with recurrent atypical meningiomas (185 lesions, 89 of which were local, 78 marginal, and 18 distant recurrences); treatment was radiosurgery (n = 60), surgery (n = 56), or both (n = 8). The median follow-up period was 53 months. Outcome measures were length of overall survival and disease-free intervals and prognostic factors for survival. RESULTS: Overall, the median progression-free survival was 26 months at the first recurrence and 100 months thereafter (the sum of the later intervals). Multivariate analysis showed that no treatment-related factors influenced prognosis, whereas recurrence at the skull base was a significant tumor-related factor limiting further treatment. Irrespective of treatment type, the recurrence-free interval was increasingly shorter during the clinical course, with a higher occurrence of marginal and distant lesions migrating to the midline and to the skull base. In sporadic cases, disease-free intervals were longer after wide craniotomy, tumor and dural resection with tumor-free margin. CONCLUSIONS: The disease-free interval was substantially similar after surgery and radiosurgery for treating recurrent disease in patients with atypical meningiomas. Surgery is the mainstay for prolonging survival, while radiosurgery can be an adjuvant strategy to gain time for clinical observation and planning aggressive surgical treatment.
OBJECTIVE: Owing to their rarity and proteiform pathologic features, the clinical behavior of atypical meningiomas is not yet well characterized. Though the extent of resection is believed to be a key determinant of prognosis, limited data exist regarding optimal management of patients with recurrent disease. METHODS: In this 20-year retrospective case series, we reviewed the medical records of 46 patients with recurrent atypical meningiomas (185 lesions, 89 of which were local, 78 marginal, and 18 distant recurrences); treatment was radiosurgery (n = 60), surgery (n = 56), or both (n = 8). The median follow-up period was 53 months. Outcome measures were length of overall survival and disease-free intervals and prognostic factors for survival. RESULTS: Overall, the median progression-free survival was 26 months at the first recurrence and 100 months thereafter (the sum of the later intervals). Multivariate analysis showed that no treatment-related factors influenced prognosis, whereas recurrence at the skull base was a significant tumor-related factor limiting further treatment. Irrespective of treatment type, the recurrence-free interval was increasingly shorter during the clinical course, with a higher occurrence of marginal and distant lesions migrating to the midline and to the skull base. In sporadic cases, disease-free intervals were longer after wide craniotomy, tumor and dural resection with tumor-free margin. CONCLUSIONS: The disease-free interval was substantially similar after surgery and radiosurgery for treating recurrent disease in patients with atypical meningiomas. Surgery is the mainstay for prolonging survival, while radiosurgery can be an adjuvant strategy to gain time for clinical observation and planning aggressive surgical treatment.
Authors: William C Chen; Jared Hara; Stephen T Magill; Ashley Wu; Manish K Aghi; Philip V Theodosopoulos; Arie Perry; Michael W McDermott; Penny K Sneed; David R Raleigh; Steve E Braunstein Journal: J Neurooncol Date: 2018-02-26 Impact factor: 4.130
Authors: C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-29 Impact factor: 7.038
Authors: Naureen Keric; Darius Kalasauskas; Christian F Freyschlag; Jens Gempt; Martin Misch; Alicia Poplawski; Nicole Lange; Ali Ayyad; Claudius Thomé; Peter Vajkoczy; Bernhard Meyer; Florian Ringel Journal: J Neurooncol Date: 2020-01-03 Impact factor: 4.130